The aim of this pilot study was to analyse the transcriptomic profile of patients suffering from metastatic melanoma without BRAF mutations in order to evaluate the possible differences in the expression profiles between advanced melanoma cells and non-dysplastic melanocytes serving as the healthy control. This evidence concerns the gene BRAF and metastatic melanoma.